ᱠᱳᱵᱷᱤᱰ-᱑᱙ ᱴᱤᱠᱟᱹ

ᱣᱤᱠᱤᱯᱤᱰᱤᱭᱟ, ᱨᱟᱲᱟ ᱜᱮᱭᱟᱱ ᱯᱩᱛᱷᱤ ᱠᱷᱚᱱ
Jump to navigation Jump to search
ᱠᱚᱢ ᱠᱟᱛᱮ ᱦᱚᱸ ᱠᱳᱵᱷᱤᱰ-᱑᱙ ᱴᱤᱠᱟᱹ ᱨᱮᱭᱟᱜ ᱢᱤᱫ ᱴᱮᱱ ᱰᱳᱡᱽ ᱠᱚ ᱧᱟᱢ ᱟᱠᱟᱱ ᱦᱚᱲ ᱠᱚᱣᱟᱜ ᱦᱟᱹᱴᱤᱧ
Map of countries by approval status
  Approved for general use, mass vaccination underway
  EUA (or equivalent) granted, mass vaccination underway
  EUA granted, limited vaccination
  Approved for general use, mass vaccination planned
  EUA granted, mass vaccination planned
  EUA pending
  No data available

ᱠᱳᱵᱷᱤᱰ-᱑᱙ ᱴᱤᱠᱟᱹ ᱫᱚ ᱢᱤᱫ ᱴᱤᱠᱟᱹ ᱠᱟᱱᱟ, ᱡᱟᱦᱟᱸ ᱫᱚ ᱟᱹᱰᱤ ᱜᱟᱹᱦᱤᱨ ᱛᱮ ᱥᱟᱦᱮᱫ ᱭᱚᱱᱟᱛᱨᱚ ᱨᱮ ᱟᱡᱟᱨ ᱥᱤᱨᱡᱚᱱᱮᱫ ᱠᱚᱨᱳᱱᱟᱵᱷᱟᱭᱨᱟᱥ ᱒ (ᱥᱟᱨᱥ-ᱠᱳᱵᱷ-᱒) ᱵᱤᱨᱩᱫᱽ ᱨᱮ ᱞᱟᱹᱲᱦᱟᱭ ᱨᱮ ᱥᱩᱨᱚᱠᱠᱷᱟ ᱮ ᱮᱢᱚᱜᱼᱟ, ᱡᱟᱦᱟᱸ ᱫᱚ ᱠᱚᱨᱳᱱᱟᱵᱷᱟᱭᱨᱟᱥ ᱟᱡᱟᱨ ᱒᱐᱑᱙ (ᱠᱳᱵᱷᱤᱰ-᱑᱙) ᱠᱷᱟᱹᱛᱤᱨ ᱛᱮ ᱦᱩᱭᱩᱜ ᱠᱟᱱᱟ ᱾ ᱱᱚᱣᱟ ᱢᱟᱨᱟᱝ ᱨᱮ, ᱠᱚᱨᱳᱱᱟᱵᱷᱟᱭᱨᱟᱥ ᱛᱮ ᱦᱩᱭᱩᱜ ᱠᱟᱱ ᱟᱹᱰᱤ ᱜᱟᱹᱦᱤᱨ ᱛᱮ ᱥᱟᱦᱮᱫ ᱭᱚᱱᱟᱛᱨᱚ ᱨᱮ ᱟᱡᱟᱨ ᱥᱤᱨᱡᱚᱱᱮᱫ ᱠᱚᱨᱳᱱᱟᱵᱷᱟᱭᱨᱟᱥ (ᱥᱟᱨᱥ) ᱟᱨ ᱥᱟᱢᱟᱝ ᱛᱟᱞᱢᱟ ᱨᱮᱥᱯᱤᱨᱮᱴᱳᱨᱤ ᱥᱤᱱᱰᱨᱳᱢ (ᱢᱟᱨᱥ) ᱵᱤᱨᱩᱫᱽ ᱨᱮ ᱞᱟᱹᱠᱛᱤᱭᱟᱱ ᱴᱤᱠᱟᱹ ᱵᱮᱱᱟᱣ ᱨᱮᱭᱟᱜ ᱡᱚᱥ ᱛᱮ ᱦᱩᱭ ᱞᱮᱱ ᱠᱷᱚᱸᱫᱽᱨᱚᱱ ᱠᱟᱹᱢᱤ ᱠᱚ ᱠᱷᱚᱱ ᱠᱚᱨᱳᱱᱟᱵᱷᱟᱭᱨᱟᱥ ᱨᱮᱭᱟᱜ ᱟᱠᱟᱨ ᱟᱨ ᱠᱟᱹᱢᱤᱦᱚᱨᱟ ᱵᱟᱵᱚᱛ ᱟᱹᱠᱤᱞ ᱜᱮᱭᱟᱱ ᱛᱟᱦᱮ ᱠᱟᱱᱟ; ᱟᱨ ᱱᱚᱣᱟ ᱠᱷᱚᱸᱫᱽᱨᱚᱱ ᱜᱮᱭᱟᱱ ᱜᱮ ᱒᱐᱒᱐ ᱥᱮᱨᱢᱟ ᱨᱮᱭᱟᱜ ᱮᱛᱚᱦᱚᱵ ᱨᱮ ᱟᱭᱢᱟ ᱴᱤᱠᱟᱹ ᱵᱮᱱᱟᱣ ᱠᱟᱹᱢᱤᱦᱚᱨᱟᱭ ᱞᱟᱦᱟ ᱤᱫᱤ ᱞᱮᱫᱟ ᱾[᱑] ᱥᱟᱨᱥ-ᱠᱳᱵᱷ-᱒ ᱴᱤᱠᱟᱹ ᱨᱮᱭᱟᱜ ᱮᱛᱚᱦᱚᱵ ᱡᱚᱥ ᱫᱚ ᱛᱟᱦᱮ ᱠᱟᱱᱟ ᱧᱮᱞᱚᱜ ᱠᱟᱱ ᱞᱚᱠᱠᱷᱚᱱ ᱟᱨ ᱟᱹᱰᱤ ᱜᱟᱹᱦᱤᱨ ᱛᱮ ᱨᱩᱣᱟᱹᱜ ᱨᱮᱭᱟᱜ ᱨᱩᱠᱷᱤᱭᱟᱹ ᱾[᱒] ᱑᱐ ᱡᱟᱱᱩᱣᱟᱨᱤ ᱒᱐᱒᱐ ᱨᱮ, ᱡᱤ.ᱟᱭ.ᱮᱥ.ᱮ.ᱟᱭ.ᱰᱤ ᱦᱚᱛᱮᱛᱮ ᱥᱟᱨᱥ-ᱠᱳᱵᱷ-᱒ ᱨᱮᱭᱟᱜ ᱡᱮᱱᱮᱴᱤᱠ ᱥᱤᱠᱳᱭᱮᱱᱥ ᱰᱮᱴᱟ ᱦᱟᱹᱴᱤᱧ ᱦᱩᱭ ᱞᱮᱱᱟ, ᱟᱨ ᱑᱙ ᱢᱟᱨᱪ ᱛᱮᱜᱮ, ᱡᱮᱜᱮᱛ ᱨᱮᱱ ᱢᱟᱨᱟᱝ ᱨᱟᱱ ᱵᱮᱱᱟᱣ ᱤᱱᱰᱟᱥᱴᱨᱤᱥ ᱠᱚ ᱱᱚᱣᱟ ᱠᱳᱵᱷᱤᱰ-᱑᱙ ᱨᱩᱠᱷᱤᱭᱟᱹ ᱞᱟᱹᱜᱤᱫ ᱠᱚ ᱠᱨᱤᱭᱟᱹ ᱞᱮᱫᱟ ᱾[᱓] ᱠᱳᱵᱷᱤᱰ-᱑᱙ ᱴᱤᱠᱟᱹ ᱠᱚᱫᱚ ᱠᱳᱵᱷᱤᱰ-᱑᱙ ᱠᱷᱟᱹᱛᱤᱨ ᱛᱮ ᱦᱩᱭᱩᱜ ᱠᱟᱱ ᱨᱩᱣᱟᱹ, ᱯᱟᱥᱱᱟᱣ ᱟᱨ ᱜᱚᱡ ᱜᱩᱨ ᱠᱚᱢ ᱚᱪᱚ ᱞᱟᱹᱜᱤᱫ ᱠᱚ ᱥᱟᱨᱦᱟᱣ ᱟᱠᱟᱫᱟ ᱾[᱔]

ᱮᱛᱚᱦᱚᱵ ᱠᱟᱛᱷᱟ[ᱥᱟᱯᱲᱟᱣ | ᱯᱷᱮᱰᱟᱛ ᱥᱟᱯᱲᱟᱣ]

ᱠᱳᱵᱷᱤᱰ-᱑᱙ ᱨᱮᱭᱟᱜ ᱚᱨᱥᱚᱝ ᱞᱟᱦᱟ ᱨᱮ, ᱵᱟᱨᱼᱯᱮ ᱥᱮᱨᱢᱟ ᱢᱩᱸᱫᱽ ᱨᱮ ᱢᱤᱫ ᱯᱟᱥᱱᱟᱣᱚᱜ ᱟᱡᱟᱨ ᱨᱮᱭᱟᱜ ᱨᱮᱭᱟᱜ ᱴᱤᱠᱟᱹ ᱫᱚ ᱱᱚᱣᱟ ᱞᱟᱦᱟ ᱨᱮ ᱵᱟᱝ ᱵᱮᱱᱟᱣ ᱟᱠᱟᱱᱟ ᱟᱨ ᱢᱟᱹᱱᱢᱤ ᱠᱚ ᱛᱟᱞᱟ ᱨᱮ ᱠᱚᱨᱳᱱᱟᱵᱷᱟᱭᱨᱟᱥ ᱟᱡᱟᱨ ᱯᱟᱥᱱᱟᱣ ᱵᱤᱨᱩᱫᱽ ᱞᱟᱹᱜᱤᱫ ᱱᱚᱣᱟ ᱢᱟᱨᱟᱝ ᱨᱮ ᱪᱮᱫ ᱴᱤᱠᱟᱹ ᱦᱚᱸ ᱵᱟᱝ ᱛᱟᱦᱮ ᱠᱟᱱᱟ ᱾[᱕] ᱛᱚᱵᱮ ᱡᱟᱱᱣᱟᱨ ᱠᱚ ᱵᱮᱵᱷᱟᱨ ᱞᱟᱹᱜᱤᱫ ᱟᱭᱢᱟ ᱜᱟᱱ ᱠᱚᱨᱳᱱᱟᱵᱷᱟᱭᱨᱟᱥ ᱴᱤᱠᱟᱹ ᱫᱚ ᱛᱮᱭᱟᱨ ᱦᱩᱭ ᱟᱠᱟᱱᱟ, ᱡᱟᱦᱟᱸ ᱠᱚ ᱢᱩᱸᱫᱽ ᱨᱮ ᱪᱮᱬᱮᱸ ᱠᱚᱣᱟᱜ ᱤᱱᱯᱷᱮᱠᱥᱤᱭᱟᱥ ᱵᱽᱨᱳᱝᱠᱟᱭᱴᱤᱥ ᱵᱷᱟᱭᱨᱟᱥ, ᱠᱮᱱᱟᱭᱤᱱ ᱠᱚᱨᱳᱱᱟᱵᱷᱟᱭᱨᱟᱥ ᱟᱨ ᱯᱷᱤᱞᱟᱭᱤᱱ ᱠᱚᱨᱳᱱᱟᱵᱷᱟᱭᱨᱟᱥ ᱥᱮᱞᱮᱫ ᱢᱮᱱᱟᱜᱼᱟ ᱾[᱖] ᱠᱚᱨᱳᱱᱟᱵᱷᱤᱨᱤᱰᱤ ᱜᱷᱟᱨᱚᱸᱡᱽ ᱨᱮᱭᱟᱜ ᱡᱟᱦᱟᱸ ᱵᱷᱟᱭᱨᱟᱥ ᱠᱚ ᱢᱟᱹᱱᱢᱤ ᱴᱷᱮᱱ ᱟᱡᱟᱨ ᱮ ᱥᱤᱨᱡᱚᱱ ᱟᱠᱟᱱᱟ ᱚᱱᱟ ᱠᱚ ᱢᱩᱸᱫᱽ ᱨᱮ ᱟᱹᱰᱤ ᱜᱟᱹᱦᱤᱨ ᱛᱮ ᱥᱟᱦᱮᱫ ᱭᱚᱱᱟᱛᱨᱚ ᱨᱮ ᱟᱡᱟᱨ ᱥᱤᱨᱡᱚᱱᱮᱫ ᱠᱚᱨᱳᱱᱟᱵᱷᱟᱭᱨᱟᱥ (ᱥᱟᱨᱥ)[᱗] ᱟᱨ ᱥᱟᱢᱟᱝ ᱛᱟᱞᱢᱟ ᱨᱮᱥᱯᱤᱨᱮᱴᱳᱨᱤ ᱥᱤᱱᱰᱨᱳᱢ (ᱢᱟᱨᱥ)[᱘] ᱟᱡᱟᱨ ᱤᱫᱤ ᱠᱟᱛᱮ ᱜᱮ ᱢᱟᱨᱟᱝ ᱨᱮ ᱴᱤᱠᱟᱹ ᱵᱮᱱᱟᱣ ᱨᱮᱭᱟᱜ ᱠᱩᱨᱩᱢᱩᱴᱩ ᱦᱩᱭ ᱞᱮᱱᱟ, ᱡᱟᱦᱟᱸ ᱫᱚ ᱢᱟᱹᱱᱢᱤ ᱵᱮᱜᱚᱨ ᱮᱴᱟᱜ ᱡᱟᱱᱩᱣᱟᱨ ᱪᱮᱛᱟᱱ ᱨᱮ ᱴᱮᱥᱴ ᱦᱩᱭ ᱞᱮᱱᱟ ᱾ ᱒᱐᱐᱕ ᱟᱨ ᱒᱐᱐᱖ ᱥᱮᱨᱢᱟ ᱨᱮ ᱚᱰᱚᱜ ᱞᱮᱱ ᱢᱤᱫ ᱠᱷᱚᱸᱫᱽᱨᱚᱱ ᱥᱟᱠᱟᱢ ᱞᱮᱠᱟᱛᱮ, ᱩᱱ ᱚᱠᱛᱚ ᱥᱟᱨᱥ ᱞᱟᱹᱜᱤᱫ ᱴᱤᱠᱟᱹ ᱟᱨ ᱨᱟᱱ ᱵᱮᱱᱟᱣ ᱜᱮ ᱡᱮᱜᱮᱛ ᱨᱮᱭᱟᱜ ᱟᱭᱢᱟ ᱥᱚᱨᱠᱟᱨ ᱟᱨ ᱦᱚᱨᱢᱚ ᱵᱷᱟᱹᱞᱟᱹᱭ ᱜᱟᱶᱛᱟ ᱟᱜ ᱢᱩᱬᱩᱛ ᱡᱚᱥ ᱛᱟᱦᱮ ᱠᱟᱱᱟ ᱾[᱙][᱑᱐][᱑᱑]

ᱢᱟᱹᱱᱢᱤ ᱞᱟᱹᱜᱤᱫ ᱥᱟᱨᱥ ᱵᱤᱨᱩᱫᱽ ᱨᱮ ᱞᱟᱹᱲᱦᱟᱭ ᱞᱟᱹᱜᱤᱫ ᱪᱮᱫ ᱯᱨᱚᱢᱟᱱ ᱴᱤᱠᱟᱹ ᱫᱚ ᱵᱟᱹᱱᱩᱜᱼᱟ ᱾[᱑᱒][᱑᱓] ᱟᱨ ᱢᱟᱨᱥ ᱠᱷᱚᱱ ᱵᱟᱧᱪᱟᱣᱚᱜ ᱞᱟᱹᱜᱤᱫ ᱦᱚᱸ ᱪᱮᱫ ᱴᱤᱠᱟᱹ ᱫᱚ ᱱᱤᱛ ᱦᱟᱹᱵᱤᱫ ᱵᱟᱝ ᱛᱮᱭᱟᱨ ᱟᱠᱟᱱᱟ ᱾[᱑᱔] ᱢᱟᱨᱥ ᱟᱡᱟᱨ ᱨᱮᱭᱟᱜ ᱚᱨᱥᱚᱝ ᱡᱚᱠᱷᱚᱱ ᱰᱷᱮᱨ ᱞᱮᱱᱟ, ᱩᱱ ᱚᱠᱛᱚ ᱵᱟᱹᱵᱤᱛ ᱦᱩᱭ ᱞᱮᱱᱟ ᱥᱟᱨᱥ ᱞᱟᱹᱜᱤᱫ ᱦᱩᱭ ᱟᱠᱟᱱ ᱠᱷᱚᱸᱫᱽᱨᱚᱱ ᱠᱚᱜᱮ ᱢᱟᱨᱥ ᱟᱡᱟᱨ ᱵᱤᱨᱩᱫᱽ ᱨᱮ ᱴᱤᱠᱟᱹ ᱟᱨ ᱛᱤᱠᱤᱪᱷᱟᱹ ᱥᱟᱬᱮᱥ ᱥᱤᱨᱚᱱ ᱨᱮᱭᱟᱜ ᱜᱚᱲᱚ ᱵᱷᱤᱛ ᱞᱮᱠᱟᱛᱮᱭ ᱠᱟᱹᱢᱤᱭᱟ ᱾[᱑᱒][᱑᱕] ᱒᱐᱒᱐ ᱨᱮᱭᱟᱜ ᱢᱟᱨᱪ ᱦᱟᱹᱵᱤᱫ ᱛᱮ ᱠᱷᱟᱹᱞᱤ ᱢᱤᱫ (ᱰᱤ.ᱮᱱ.ᱮ) ᱴᱮᱱ ᱢᱟᱨᱥ ᱴᱤᱠᱟᱹ ᱛᱮᱭᱟᱨ ᱦᱩᱭ ᱟᱠᱟᱱ ᱡᱟᱦᱟᱸ ᱫᱚ ᱢᱟᱹᱱᱢᱤ ᱪᱮᱫ ᱵᱤᱰᱟᱹᱣ (ᱴᱮᱥᱴ) ᱨᱮᱭᱟᱜ ᱯᱩᱭᱞᱩ ᱛᱷᱟᱨ ᱮ ᱯᱟᱨᱚᱢ ᱟᱠᱟᱫᱟ ᱾[᱑᱖] ᱟᱨ ᱟᱨᱦᱚᱸ ᱯᱮᱭᱟ ᱠᱷᱚᱸᱫᱽᱨᱚᱱ ᱪᱟᱞᱟᱜ ᱠᱟᱱᱟ, ᱱᱚᱣᱟ ᱠᱚ ᱢᱩᱸᱫᱽ ᱨᱮ ᱥᱟᱱᱟᱢ ᱜᱮ ᱵᱷᱟᱭᱨᱟᱥᱤᱭᱟᱹ ᱜᱮᱢᱮᱨ ᱴᱤᱠᱟᱹ ᱠᱟᱱᱟ; ᱱᱚᱣᱟ ᱠᱚ ᱢᱩᱸᱫᱽ ᱨᱮ ᱵᱟᱨᱭᱟ ᱫᱚ ᱮᱰᱮᱱᱳᱵᱷᱥᱭᱨᱟᱞ-ᱵᱷᱮᱠᱴᱳᱨᱰ ᱜᱮᱢᱮᱨ ᱴᱤᱠᱟᱹ (ChAdOx1-MERS, BVRS-GamVac) ᱟᱨ ᱢᱤᱫ ᱴᱮᱱ ᱫᱚ ᱮᱢ.ᱵᱷᱤ.ᱮ ᱜᱮᱢᱮᱨ ᱴᱤᱠᱟᱹ ᱠᱟᱱᱟ ᱾[᱑᱗]

ᱯᱚᱨᱛᱚᱱ ᱟᱨ ᱩᱛᱷᱱᱟᱹᱣ[ᱥᱟᱯᱲᱟᱣ | ᱯᱷᱮᱰᱟᱛ ᱥᱟᱯᱲᱟᱣ]

᱒᱐᱒᱐ ᱨᱮᱭᱟᱜ ᱠᱩᱨᱩᱢᱩᱴᱩ[ᱥᱟᱯᱲᱟᱣ | ᱯᱷᱮᱰᱟᱛ ᱥᱟᱯᱲᱟᱣ]

ᱴᱤᱠᱟᱹ ᱨᱮᱭᱟᱜ ᱫᱷᱚᱨᱚᱱ (ᱞᱮᱠᱟᱱ)[ᱥᱟᱯᱲᱟᱣ | ᱯᱷᱮᱰᱟᱛ ᱥᱟᱯᱲᱟᱣ]

ᱵᱟᱹᱨᱤᱪ ᱚᱨᱥᱚᱝ (ᱥᱟᱭᱤᱰ ᱮᱯᱷᱮᱠᱴ)[ᱥᱟᱯᱲᱟᱣ | ᱯᱷᱮᱰᱟᱛ ᱥᱟᱯᱲᱟᱣ]

ᱴᱤᱠᱟᱹ ᱠᱚ[ᱥᱟᱯᱲᱟᱣ | ᱯᱷᱮᱰᱟᱛ ᱥᱟᱯᱲᱟᱣ]

ᱵᱟᱨᱦᱮ ᱡᱚᱱᱚᱲ[ᱥᱟᱯᱲᱟᱣ | ᱯᱷᱮᱰᱟᱛ ᱥᱟᱯᱲᱟᱣ]

ᱥᱟᱹᱠᱷᱟᱹᱭᱟᱹᱛ[ᱥᱟᱯᱲᱟᱣ | ᱯᱷᱮᱰᱟᱛ ᱥᱟᱯᱲᱟᱣ]

  1. Li YD, Chi WY, Su JH, Ferrall L, Hung CF, Wu TC (ᱰᱤᱥᱮᱢᱵᱚᱨ 2020). "Coronavirus vaccine development: from SARS and MERS to COVID-19". Journal of Biomedical Science. 27 (1): 104. doi:10.1186/s12929-020-00695-2. PMC 7749790Freely accessible Check |pmc= value (help). PMID 33341119 Check |pmid= value (help). 
  2. Subbarao, Kanta (ᱡᱩᱞᱟᱭ 2021). "The success of SARS-CoV-2 vaccines and challenges ahead". Cell Host & Microbe. 29 (7): 1111–1123. doi:10.1016/j.chom.2021.06.016. PMC 8279572Freely accessible Check |pmc= value (help). PMID 34265245 Check |pmid= value (help). 
  3. Padilla TB (24 ᱯᱷᱮᱵᱽᱨᱩᱣᱟᱨᱤ 2021). "No one is safe unless everyone is safe". BusinessWorld. Retrieved 24 ᱯᱷᱮᱵᱽᱨᱩᱣᱟᱨᱤ 2021. 
  4. Vergano, Dan (5 ᱡᱩᱱ 2021). "COVID-19 Vaccines Work Way Better Than We Had Ever Expected. Scientists Are Still Figuring Out Why". BuzzFeed News. Retrieved 24 ᱡᱩᱱ 2021. 
  5. Gates B (30 ᱮᱯᱨᱤᱞ 2020). "The vaccine race explained: What you need to know about the COVID-19 vaccine". The Gates Notes. Archived from the original on 14 ᱢᱮ 2020. Retrieved 2 ᱢᱮ 2020.  Unknown parameter |name-list-style= ignored (help); Unknown parameter |url-status= ignored (help)
  6. Cavanagh D (ᱰᱤᱥᱮᱢᱵᱚᱨ 2003). "Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus". Avian Pathology. 32 (6): 567–82. doi:10.1080/03079450310001621198Freely accessible. PMC 7154303Freely accessible Check |pmc= value (help). PMID 14676007. 
  7. Gao W, Tamin A, Soloff A, D'Aiuto L, Nwanegbo E, Robbins PD, et al. (ᱰᱤᱥᱮᱢᱵᱚᱨ 2003). "Effects of a SARS-associated coronavirus vaccine in monkeys". Lancet. 362 (9399): 1895–96. doi:10.1016/S0140-6736(03)14962-8Freely accessible. PMC 7112457Freely accessible Check |pmc= value (help). PMID 14667748 //www.ncbi.nlm.nih.gov/pmc/articles/PMC7112457 |PMC= missing title (help). 
  8. Kim E, Okada K, Kenniston T, Raj VS, AlHajri MM, Farag EA, et al. (ᱚᱠᱴᱚᱵᱚᱨ 2014). "Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice". Vaccine. 32 (45): 5975–82. doi:10.1016/j.vaccine.2014.08.058. PMC 7115510Freely accessible Check |pmc= value (help). PMID 25192975. 
  9. Greenough TC, Babcock GJ, Roberts A, Hernandez HJ, Thomas WD, Coccia JA, et al. (ᱯᱷᱮᱵᱽᱨᱩᱣᱟᱨᱤ 2005). "Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice". The Journal of Infectious Diseases. 191 (4): 507–14. doi:10.1086/427242. PMC 7110081Freely accessible Check |pmc= value (help). PMID 15655773. 
  10. Tripp RA, Haynes LM, Moore D, Anderson B, Tamin A, Harcourt BH, et al. (ᱥᱮᱯᱴᱮᱢᱵᱚᱨ 2005). "Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins". Journal of Virological Methods. 128 (1–2): 21–28. doi:10.1016/j.jviromet.2005.03.021. PMC 7112802Freely accessible Check |pmc= value (help). PMID 15885812. 
  11. Roberts A, Thomas WD, Guarner J, Lamirande EW, Babcock GJ, Greenough TC, et al. (ᱢᱟᱨᱪ 2006). "Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters". The Journal of Infectious Diseases. 193 (5): 685–92. doi:10.1086/500143. PMC 7109703Freely accessible Check |pmc= value (help). PMID 16453264. 
  12. ᱑᱒.᱐ ᱑᱒.᱑ Jiang S, Lu L, Du L (ᱡᱟᱱᱩᱣᱟᱨᱤ 2013). "Development of SARS vaccines and therapeutics is still needed". Future Virology. 8 (1): 1–2. doi:10.2217/fvl.12.126. PMC 7079997Freely accessible Check |pmc= value (help). PMID 32201503 Check |pmid= value (help). 
  13. "SARS (severe acute respiratory syndrome)". National Health Service. 5 ᱢᱟᱨᱪ 2020. Archived from the original on 9 ᱢᱟᱨᱪ 2020. Retrieved 31 ᱡᱟᱱᱩᱣᱟᱨᱤ 2020.  Unknown parameter |url-status= ignored (help)
  14. Shehata MM, Gomaa MR, Ali MA, Kayali G (ᱡᱩᱱ 2016). "Middle East respiratory syndrome coronavirus: a comprehensive review". Frontiers of Medicine. 10 (2): 120–36. doi:10.1007/s11684-016-0430-6. PMC 7089261Freely accessible Check |pmc= value (help). PMID 26791756.  Unknown parameter |name-list-style= ignored (help)
  15. Butler D (ᱚᱠᱴᱚᱵᱚᱨ 2012). "SARS veterans tackle coronavirus". Nature. 490 (7418): 20. Bibcode:2012Natur.490...20B. doi:10.1038/490020aFreely accessible. PMID 23038444. 
  16. Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, et al. (ᱥᱮᱯᱴᱮᱢᱵᱚᱨ 2019). "Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial". The Lancet. Infectious Diseases. 19 (9): 1013–22. doi:10.1016/S1473-3099(19)30266-XFreely accessible. PMC 7185789Freely accessible Check |pmc= value (help). PMID 31351922 //www.ncbi.nlm.nih.gov/pmc/articles/PMC7185789 |PMC= missing title (help). 
  17. Yong CY, Ong HK, Yeap SK, Ho KL, Tan WS (2019). "Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus". Frontiers in Microbiology. 10: 1781. doi:10.3389/fmicb.2019.01781Freely accessible. PMC 6688523Freely accessible Check |pmc= value (help). PMID 31428074.